• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Senzime

4.16 SEK+0.73 %15.7, 9.11
Less than 1K followers

SEZI

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.73 %
-3.03 %
-13.24 %
-18.91 %
-22.96 %
-21.95 %
-21.06 %
-82.99 %
-29.90 %

Senzime operates in the medical technology industry and focuses on the development and manufacture of systems for monitoring and diagnostics in healthcare. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. The company's products are aimed at healthcare institutions and physicians. The operations are global. Senzime was founded in 1999 and is headquartered in Uppsala, Sweden.

Read more
Market cap
654.01M SEK
Turnover
2.68K SEK
Revenue
104.02M
EBIT %
-117.84 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
16.7
2026

Interim report Q2'26

29.10
2026

Interim report Q3'26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release13.07.2026, 12.00

Invitation to presentations of Senzime’s second quarter 2026 report

Senzime
Press release29.06.2026, 09.00

Senzime’s TetraGraph system receives ANVISA regulatory approval in Brazil

Senzime
Press release05.06.2026, 10.00

Senzime to Showcase Expanded TetraGraph Capabilities with Launch of TetraAnalytics at Euroanaesthesia 2026

Senzime

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release03.06.2026, 11.45

Senzime strengthens position in pediatric anesthesia by securing another hospital contract and highlighting positive outcome data

Senzime
Press release01.06.2026, 11.00

Senzime Advances Sustainable Anesthesia Monitoring with Launch of New EMG Sensor

Senzime
Press release27.05.2026, 11.15

From science to practice: Senzime obtains FDA 510(k) clearance for enhanced TetraGraph system

Senzime
Regulatory press release19.05.2026, 17.45

BULLETIN FROM ANNUAL GENERAL MEETING IN SENZIME AB (PUBL)

Senzime
Press release29.04.2026, 14.15

Senzime strengthens U.S. operations with new leadership appointments

Senzime
Press release24.04.2026, 13.30

Senzime’s TetraGraph System Contracted on Three Leading GPO Agreements in the US

Senzime
Regulatory press release24.04.2026, 12.00

Senzime publishes annual and sustainability report for 2025

Senzime
Press release23.04.2026, 09.34

Redeye: Senzime (Q1 Review): Temporary growth dip, with Q2 recovery expected

Senzime
Regulatory press release22.04.2026, 08.00

Margins strengthened and cash flow improved despite a temporary dip in the growth trajectory. Full-year targets remain on track.

Senzime
Press release20.04.2026, 09.00

Senzime wins expanded contract within leading southeastern US hospital system

Senzime
Regulatory press release17.04.2026, 17.30

NOTICE OF ANNUAL GENERAL MEETING IN Senzime AB (publ)

Senzime
Press release17.04.2026, 10.00

Invitation to presentations of Senzime’s first quarter 2026 report

Senzime
Press release09.04.2026, 14.00

Senzime secures strategic hospital orders within leading US integrated healthcare delivery network

Senzime
Press release19.02.2026, 09.35

Redeye: Senzime (Q4 Review): Solid report and a positive 2026 outlook

Senzime
Press release19.02.2026, 09.00

Senzime launches TetraCom connectivity platform enabling universal transmission of anesthesia data

Senzime
Press release18.02.2026, 11.30

Redeye: Senzime (Q4 Initial take): Sales spot on to our estimate

Senzime
Regulatory press release18.02.2026, 08.30

Senzime Q4 2025: Accelerated growth and continued clear path to profitability

Senzime